# Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects

> **NCT04540965** · PHASE1 · COMPLETED · sponsor: **Calithera Biosciences, Inc** · enrollment: 22 (actual)

## Conditions studied

- Drug Interaction

## Interventions

- **DRUG:** Telaglenastat
- **DRUG:** Famotidine
- **DRUG:** Placebo for famotidine

## Key facts

- **NCT ID:** NCT04540965
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-22
- **Primary completion:** 2020-12-08
- **Final completion:** 2020-12-08
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540965, "Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04540965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*